Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has accepted EntreMed's investigational new drug application for ENMD-1198, a novel tubulin binding agent that the company wishes to move into clinical development for the treatment of cancer.
Subscribe to our email newsletter
ENMD-1198 is a new chemical entity designed to increase anti-tumor and anti-angiogenic properties and improve metabolism. The drug is characterized by its multiple mechanisms of action, which include inducing apoptosis, binding microtubules, and inhibiting HIF-1alpha. HIF-1alpha is over-expressed in more than 70% of human tumors and its over-expression correlates with tumor aggressiveness, metastases and poor prognosis.
Preclinical studies identified ENMD-1198 as an orally active, microtubule disrupting agent that leads to arrest of cell division and apoptosis in tumor cells. Additionally, ENMD-1198 exerts antiangiogenic activity that contributes to its overall anti-tumor effects.
Oral daily treatment with ENMD-1198 in an orthotopic breast cancer model led to a reduction in tumor burden equivalent to the positive control cyclophosphamide, disruption of microtubules within tumor cells, and a substantial decrease in HIF-1alpha.